A) The glioblastoma cell lines U87, A172, U373, U251, T98G, U1242, SNB-19, SF-767, primary GBM cells GBM-6 and GBM-10, GBM stem cells XO-1, 2, 3, 4, 8, 9 and 206, 827 and 578 were lysed and immunoblotted for Cav3.2 and/or β-actin/GAPDH loading controls. B) Primary GBM cells (other than the ones of ) were sorted for CD133 expression by FACS and subjected to quantitative RT-PCR to determine the expression of CD133, SOX2, GFAP and Cav3.2. C) GBM human specimens G1-G31 and normal brains N1-4 were subjected to immunoblotting for Cav3.2 and β-Actin. D) TCGA (upper panel) and REMBRANDT (lower panel) data analyses of Cav3.2 (CACNA1H) mRNA expression and correlation with patient survival, Provisional, mRNA Expression z-Scores (RNA Seq V2 RSEM, with a z0score threshold 1.0) in upper panel. The analyses showed worse survival with high expression of Cav3.2. The above data show high expression of Cav3.2 in a subset of GBM and GSC and a trend towards inverse correlation with patient survival.